Ribavirin in the treatment of SARS: A new trick for an old drug?

The dramatic outbreak of severe acute respiratory syndrome (SARS) has led to the use of high-dose intravenous and oral ribavirin in patients affected with this disorder. Ribavirin, a nucleoside analogue with broad antiviral activity, was discovered in 1970 by ICN Pharmaceuticals. In Canada, ribavirin is licensed for the treatment of respiratory syncytial virus (RSV) infection in infants and, in combination with interferon α2b, hepatitis C. In view of the limited circumstances in which it is prescribed, most physicians are not familiar with its pharmacology, dosing and safety. In this article we summarize this information for the benefit of health care professionals who may be involved with patients receiving ribavirin for treatment or prevention of SARS. We also review emerging data on the potential efficacy of ribavirin against the SARS virus, a new mutant of coronavirus.

[1]  Peter Cameron,et al.  A major outbreak of severe acute respiratory syndrome in Hong Kong. , 2003, The New England journal of medicine.

[2]  Arthur S Slutsky,et al.  Identification of severe acute respiratory syndrome in Canada. , 2003, The New England journal of medicine.

[3]  M. Chan-yeung,et al.  A cluster of cases of severe acute respiratory syndrome in Hong Kong. , 2003, The New England journal of medicine.

[4]  T. Wright,et al.  The safety and tolerability of daily infergen plus ribavirin in the treatment of naíïve chronic hepatitis C patients , 2003, Journal of viral hepatitis.

[5]  M. Lai,et al.  Meta‐analysis: ribavirin‐induced haemolytic anaemia in patients with chronic hepatitis C , 2002, Alimentary pharmacology & therapeutics.

[6]  S. Schulman.  Inhibition of Warfarin Activity by Ribavirin , 2002, The Annals of pharmacotherapy.

[7]  C. Cameron,et al.  The mechanism of action of ribavirin: lethal mutagenesis of RNA virus genomes mediated by the viral RNA-dependent RNA polymerase , 2001, Current opinion in infectious diseases.

[8]  A. Lafeuillade,et al.  Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection , 2001, The Lancet.

[9]  A. Tzakis,et al.  Intravenous Ribavirin and Hyperammonemia in an Immunocompromised Patient Infected with Adenovirus , 2000, Pharmacotherapy.

[10]  A. Chutaputti.  Adverse effects and other safety aspects of the hepatitis C antivirals , 2000, Journal of gastroenterology and hepatology.

[11]  R. Holman,et al.  Intravenous Ribavirin for Hantavirus Pulmonary Syndrome: Safety and Tolerance during 1 Year of Open-Label Experience , 1998, Antiviral therapy.

[12]  P. Glue,et al.  The clinical pharmacology of ribavirin. , 1999, Seminars in liver disease.

[13]  G. Koren,et al.  Exposure of pregnant women to ribavirin‐contaminated air: risk assessment and recommendations , 1993, The Pediatric infectious disease journal.

[14]  J. Leduc,et al.  Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome. , 1991, The Journal of infectious diseases.

[15]  D. W. Smith,et al.  A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection. , 1991, The New England journal of medicine.

[16]  Harold C. Sox,et al.  National Institutes of Health Consensus Development Conference Statement: Geriatric Assessment Methods for Clinical Decision‐making , 1988 .